^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anal Carcinoma

    2d
    Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection (clinicaltrials.gov)
    P2, N=16, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed
    Trial completion
    7d
    ANTARES: Agnostic Therapy in Rare Solid Tumors (clinicaltrials.gov)
    P2, N=28, Recruiting, Instituto do Cancer do Estado de São Paulo | Active, not recruiting --> Recruiting
    Enrollment open • IO biomarker • Pan tumor
    |
    FH (Fumarate Hydratase) • MITF (Melanocyte Inducing Transcription Factor)
    |
    Opdivo (nivolumab)
    7d
    HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (clinicaltrials.gov)
    P1, N=32, Completed, Baylor College of Medicine | Active, not recruiting --> Completed | Trial completion date: Oct 2033 --> Jan 2026
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    8d
    Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (clinicaltrials.gov)
    P=N/A, N=72, Completed, Travera Inc | Recruiting --> Completed | N=200 --> 72 | Trial completion date: Jul 2028 --> Mar 2026 | Trial primary completion date: Jul 2027 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    8d
    SAPPHIRE: Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study (clinicaltrials.gov)
    P=N/A, N=42, Not yet recruiting, Institut du Cancer de Montpellier - Val d'Aurelle
    New trial • HEOR
    9d
    ReRT: Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors (clinicaltrials.gov)
    P=N/A, N=1800, Recruiting, The New York Proton Center | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    13d
    PRESERVE-009: Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, OncoC4, Inc. | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    gotistobart (BNT316) • AI-061
    16d
    Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Jiataile (sacituzumab tirumotecan)
    19d
    Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • capecitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    22d
    Painless perianal mucinous adenocarcinoma: A case report and literature review. (PubMed, Oncol Lett)
    The patient underwent radical local wide resection 1 month later, and no recurrence or metastasis was observed during a follow-up period of 12 months. The present case report provides a real-world reference for the clinical diagnosis, selection of treatment plans and evaluation of the prognosis of painless PMA.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2)
    |
    KRAS G12D • KRAS G12
    22d
    Clinicopathology of adenocarcinoma originating from the anal gland with immunohistochemical expressions of GATA3 and TTF-1: a case report and literature review. (PubMed, Front Oncol)
    The patient received postoperative radiotherapy. At 6 months of follow-up, metastasis to the right inguinal lymph nodes was identified.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NKX2-1 (NK2 Homeobox 1) • VIM (Vimentin) • CDX2 (Caudal Type Homeobox 2) • GATA3 (GATA binding protein 3)
    |
    KRAS mutation • BRAF mutation • NRAS mutation
    28d
    RC09-FIAS: The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery (clinicaltrials.gov)
    P=N/A, N=520, Recruiting, The First Hospital of Jilin University | Not yet recruiting --> Recruiting
    Enrollment open